Patents by Inventor Matthew L. Sherman

Matthew L. Sherman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACTIVIN-ACTRIIA ANTAGONISTS FOR INHIBITING GERM CELL MATURATION
    Publication number: 20160319254
    Abstract: In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
    Type: Application
    Filed: May 6, 2016
    Publication date: November 3, 2016
    Inventors: John Knopf, Jasbir Seehra, Matthew L. Sherman
  • METHODS FOR DOSING AN ACTRIIB ANTAGONIST AND MONITORING OF TREATED PATIENTS
    Publication number: 20160279197
    Abstract: In certain aspects, the present invention provides methods for dosing a patient with an ActRIIb antagonist and methods for managing patients treated with an ActRIIb anatagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient.
    Type: Application
    Filed: January 25, 2016
    Publication date: September 29, 2016
    Inventors: Matthew L. Sherman, Niels Borgstein
  • METHODS FOR DOSING AN ACTIVIN-ACTRIIA ANTAGONIST AND MONITORING OF TREATED PATIENTS
    Publication number: 20160279203
    Abstract: In certain aspects, the present invention provides methods for dosing a patient with an activin-ActRIIa antagonist and methods for managing patients treated with an activin-ActRIIa anatagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient.
    Type: Application
    Filed: January 25, 2016
    Publication date: September 29, 2016
    Inventors: Matthew L. Sherman, Niels Borgstein
  • Activin-actriia antagonists for treating a follicle-stimulating horomone-secreting pituitary tumor
    Patent number: 9353356
    Abstract: In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: May 31, 2016
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Matthew L. Sherman
  • ANTAGONISTS OF ACTIVIN-ACTRIIA AND USES FOR INCREASING RED BLOOD CELL LEVELS
    Publication number: 20150183845
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: November 20, 2014
    Publication date: July 2, 2015
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • Follistatin Fusion Proteins and Uses Thereof
    Publication number: 20150158923
    Abstract: In certain aspects, the present invention provides methods for dosing a patient with an ActRIIb antagonist and methods for managing patients treated with an ActRIIb anatagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient.
    Type: Application
    Filed: February 13, 2015
    Publication date: June 11, 2015
    Inventors: Matthew L. Sherman, Niels Borgstein
  • Antagonists of activin-actriia and uses for increasing red blood cell levels
    Patent number: 8895016
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: November 25, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • TREATMENT OF CANCER WITH ALK1 ANTAGONISTS
    Publication number: 20140193425
    Abstract: Methods for evaluating responsiveness of a subject having cancer to treatment with an activin receptor-like kinase 1 (ALK1) antagonist are provided. Methods for selecting a subject for treatment with an ALK1 antagonist based on the subject being identified as responsive to such treatment are also provided. Some of the diagnostic methods provided herein are based on detecting an ALK1 agonist, e.g., an ALK1 ligand such as BMP9 or BMP10, in a sample obtained from the subject. Diagnostic reagents and kits for determining whether a subject is responsive to treatment with an ALK1 antagonist are also provided.
    Type: Application
    Filed: October 4, 2013
    Publication date: July 10, 2014
    Applicant: Acceleron Pharma, Inc.
    Inventors: John Knopf, Ravindra Kumar, Robert S. Pearsall, Matthew L. Sherman
  • Activin-actriia antagonists for inhibiting germ cell maturation
    Patent number: 8367611
    Abstract: In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
    Type: Grant
    Filed: May 19, 2011
    Date of Patent: February 5, 2013
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Matthew L. Sherman
  • ACTIVIN-ACTRII ANTAGONISTS AND USES FOR INCREASING RED BLOOD CELL LEVELS
    Publication number: 20120052067
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: July 22, 2011
    Publication date: March 1, 2012
    Applicant: Acceleron Pharma Inc.
    Inventor: Matthew L. Sherman
  • ANTAGONISTS OF ACTRIIB AND USES FOR INCREASING RED BLOOD CELL LEVELS
    Publication number: 20120003218
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: August 25, 2011
    Publication date: January 5, 2012
    Applicant: Acceleron Pharma Inc.
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • ACTIVIN-ACTRIIA ANTAGONISTS FOR INHIBITING GERM CELL MATURATION
    Publication number: 20110218147
    Abstract: In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
    Type: Application
    Filed: May 19, 2011
    Publication date: September 8, 2011
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Matthew L. Sherman
  • Activin-actrii antagonists and uses for increasing red blood cell levels
    Patent number: 8007809
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: August 30, 2011
    Assignee: Acceleron Pharma Inc.
    Inventor: Matthew L. Sherman
  • Activin-ActRII antagonists and uses for increasing red blood cell levels
    Patent number: 7988973
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: August 2, 2011
    Assignee: Acceleron Pharma Inc.
    Inventor: Matthew L. Sherman
  • Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
    Patent number: 7960343
    Abstract: In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: June 14, 2011
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Matthew L. Sherman
  • METHODS FOR TREATING FATTY LIVER DISEASE
    Publication number: 20110129469
    Abstract: In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease.
    Type: Application
    Filed: November 3, 2010
    Publication date: June 2, 2011
    Applicant: Acceleron Pharma Inc.
    Inventors: Alan Koncarevic, Jennifer Lachey, Jasbir Seehra, Matthew L. Sherman
  • Activin-actrii antagonists and uses for increasing red blood cell levels
    Publication number: 20100204092
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: September 29, 2008
    Publication date: August 12, 2010
    Applicant: Acceleron Pharma Inc.
    Inventor: Matthew L. Sherman
  • Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
    Patent number: 7727968
    Abstract: Methods of treatment and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia, and myelodysplastic syndrome. The methods of treatment and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog. Preferred methods of treatment and pharmaceutical combinations employ gemtuzumab ozogamicin, daunorubicin, and cytarabine.
    Type: Grant
    Filed: June 11, 2007
    Date of Patent: June 1, 2010
    Assignee: Wyeth LLC
    Inventors: Jay Marshall Feingold, Matthew L. Sherman, Lance H. Leopold, Mark Berger
  • Antagonists of activin-actriia and uses for increasing red blood cell levels
    Publication number: 20100028331
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: June 26, 2009
    Publication date: February 4, 2010
    Applicant: Acceleron Pharma Inc.
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • Antagonists of actriib and uses for increasing red blood cell levels
    Publication number: 20100028332
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: June 26, 2009
    Publication date: February 4, 2010
    Applicant: Acceleron Pharma Inc.
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein